This year has been a fruitful year for bladder cancer, with several relevant advances reshaping the therapeutic landscape. Several long-awaited studies were presented and published. These studies provided the robust data that helped move the field forward.
The results of the studies also sparked important discussions. The outcomes challenged existing paradigms and prompted a re-evaluation of what should be considered as the standard of care. From non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), to upper tract urothelial carcinoma (UTUC), all fields have been explored in 2025.
Found below are the key educational content featured on the UROONCO platform this year. These highlights combined landmark publications with expert insights and multidisciplinary discussions.
The POTOMAC trial
· Prof. Maria De Santis presents POTOMAC trial results: Dr. Benjamin Pradere interviews Prof. Maria De Santis about the result of the final analysis of the phase III, open-label, randomised POTOMAC trial: Durvalumab in combination with Bacillus Calmette-Guérin for BCG-naïve, high-risk non-muscle-invasive bladder cancer.
The CREST trial
· Dr. Neal Shore discusses phase 3 CREST study results: Dr. Benjamin Pradere talked to Dr. Neal Shore about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin improves event-free survival versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer.
· Webcast lecture: CREST
The ALBAN trial
· Prof. Roupret presents the ALBAN study: Dr. Benjamin Pradere talks to Prof. Morgan Rouprêt , on the results of the ALBAN trial, which is a phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical BCG vs BCG alone in BCG naïve high-risk NMIBC.
Challenging NMIBC management
· Dr. Bukavina discusses managing high-risk NMIBC: Dr. Elisabeth Grobet-Jeandin and Dr. Laura Mertens interview Dr. Laura Bukavina (US) on managing high-risk NMIBC.
· Dr. Guerrero-Ramos shares first results of SunRISe-1 cohort 4: Dr. Benjamin Pradere interviews Dr. Guerrero-Ramos about the study’s design, a detailed discussion of the results, comparisons with other trials such as BOND-003, and the implications for clinical practice.
These are the interviews regarding the game-changer studies
· Prof. Vulsteke presents KEYNOTE-905/EV303 study results: Dr. Benjamin Pradere talks to Prof. Christof Vulsteke on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative enfortumab vedotin plus pembrolizumab in participants with who are cisplatin-ineligible.
· Prof. Dyrskjøt talks about ctDNA in MIBC: Dr. Laura Mertens and Dr. Elisabeth Grobet-Jeandin talked to Prof. Lars Dyrskjøt (DE) about ctDNA in muscle invasive bladder cancer.
· Prof. James presents the BladderPath trial: Dr. Benjamin Pradere talks to Prof. Nicholas James on the results of the final survival analysis from the BladderPath trial, a randomised comparison of upfront magnetic resonance imaging versus transurethral resection for staging new bladder cancers.
· Round table discussion on radical cystectomy: Moderator Assoc. Prof. Jonathan Aning joins with experts Dr. Carmen Mir and Dr. Marco Moschini, discussing radical cystectomy for NMIBC, the impact of treatments for NMIBC on quality of life, patient preference and what the future holds.
Webcast of lectures and debates:
· ctDNA in muscle invasive bladder cancer: Ready for prime time?
· Theranostics in bladder cancer: Connecting diagnosis to therapy
· Imaging-driven selection for immunotherapy: Can imaging predict response to check-point inhibitors?
· Tips & tricks intracorporeal neobladder
· Prehabilitation: The impact of exercise, personalised programmes, and digital devices
Interviews regarding the game changer studies:
· Dr. Houede discusses the iNDUCT trial: Dr. Benjamin Pradere talked to Dr. Nadine Houede on the the iNDUCT trial. The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients.
Some roundtable discussions:
· When do I consider segmental ureterectomy?: Dr. Benjamin Pradere interviews Dr. Francesco Soria on the state-of-the-art lecture “When do I consider segmental ureterectomy?”
· Is there a role of PET-Glu for UTUC staging?: Dr. Benjamin Pradere talks to Dr. Bas van Rhijn on the state-of-the-art lecture he presented at UROonc25 in Seville
Webcast of lectures and debates:
· Navigating the gray zones: Challenges of risk classification in UTUC. Is the current risk classification in UTUC adequate for guiding clinical decision-making?
o In defence of current UTUC risk cassifications: A framework for effective management
o The flaws in current UTUC risk classifications: Implications for clinical outcomes and patient care
· How to manage concurrent high-grade bladder and upper tract urothelial carcinoma?